Roche acquires the TIB Molbiol Group
Berlin/ Basel (Switzerland) — A Gleiss Lutz team has advised the global pharmaceutical and diagnostics group Roche on the acquisition of all shares in the Berlin-based TIB Molbiol Group, an expert in molecular diagnostics. The closing of the transaction is subject to customary closing conditions and is expected to occur in the fourth quarter of 2021. The acquisition expands Roche’s broad portfolio in molecular diagnostics solutions with a wide range of assays for infectious diseases, such as SARS-CoV2 variants.
Roche is a global company in the research and development of medicines and diagnostics. In addition, Roche is the world’s largest biotech company with drugs for oncology, immunology, infectious diseases, ophthalmology and diseases of the
Central nervous system.
Founded in 1896 and headquartered in Basel, Switzerland, the Roche Group operates in more than 100 countries and employed more than 100,000 people worldwide in 2020. In 2020, Roche invested CHF 12.2 billion in research and development and generated sales of CHF 58.3 billion.
The biotechnology company TIB Molbiol was founded in 1990 and has been supplying the international market with diagnostic and research reagents ever since. As a manufacturer of custom oligonucleotides, the company is a partner in the development of molecular diagnostics and has a broad portfolio of diagnostic assays. The Berlin-based company has sites in the USA, Colombia, Italy, Spain and Australia.
Dr. Ruben Perren and Dr. Felix Kobel from Roche’s legal department were responsible for the transaction.
The following Gleiss Lutz team acted for Roche in the transaction:
Dr. Alexander Schwarz (Partner, Düsseldorf), Dr. Martin Viciano Gofferje (Partner, Berlin, both Lead), Dr. Fabian Mumme (Düsseldorf), Dr. Christoph Meissner (Berlin), Friedrich Baumgärtel, Kai Zimutta (both Düsseldorf, all M&A), Dr. Alexander Molle (Partner), Jan Hinrichs, Dr. Felix Müller (all IP/IT), Dr. Enno Burk (Counsel, Healthcare, all Berlin), Dr. Johann Wagner (Partner, Tax, Hamburg), Dr. Jacob von Andreae (Partner), Aylin Hoffs, Matthias Hahn, Lennart Förster (all Public Commercial Law, Düsseldorf), Dr. Ingo Brinker (Partner), Dr. Iris Benedikt-Buckenleib (Counsel, both Antitrust, Munich), Dr. Stefan Lingemann (Partner), Josefine Chakrabarti (both Berlin), Dr. Simona Kreis (Hamburg, all Labor Law), Konrad Discher (Counsel, Real Estate, Frankfurt).
Gleiss Lutz has advised Roche on several transactions in the past, including the sale of Roche Diagnostics IT Solutions GmbH to Nexus AG.